Edition:
India

Deinove SA (ALDEI.PA)

ALDEI.PA on Paris Stock Exchange

1.20EUR
8:52pm IST
Change (% chg)

€0.02 (+1.35%)
Prev Close
€1.18
Open
€1.24
Day's High
€1.24
Day's Low
€1.19
Volume
45,142
Avg. Vol
55,197
52-wk High
€3.68
52-wk Low
€1.06

Latest Key Developments (Source: Significant Developments)

US Department of Defense and Deinove Announce DNV3681 Results
Monday, 20 May 2019 

May 20 (Reuters) - DEINOVE SA ::DNV3681 DEMONSTRATED A SUPERIOR IN VITRO EFFICACY COMPARED TO CIPROFLOXACIN WHICH IS PRODUCT OF REFERENCE WHEN EXPOSED TO BACILLUS ANTHRACIS.DNV3681 IS ACTIVE MOLECULE OF DNV3837, DEVELOPED IN PARALLEL BY DEINOVE AS A POTENTIAL TREATMENT FOR GASTROINTESTINAL INFECTIONS CAUSED BY CLOSTRIDIUM DIFFICILE.  Full Article

Deinove FY Consolidated Group Loss Widens To 8.7 Million Euros
Friday, 29 Mar 2019 

March 28 (Reuters) - DEINOVE SA ::FY CONSOLIDATED GROUP LOSS EUR 8.7 MILLION VERSUS LOSS OF EUR 7.3 MILLION YEAR AGO.FY OPERATING LOSS EUR 10.5 MILLION VERSUS LOSS OF EUR 9.7 MILLION YEAR AGO.FY OPERATING REVENUE EUR 0.8 MILLION VERSUS EUR 0.2 MILLION YEAR AGO.  Full Article

Deinove Prepares Phase II For DNV3837 In Clostridium Difficile Infections
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - DEINOVE SA ::DEINOVE IS PREPARING INITIATION OF PHASE II FOR DNV3837 IN CLOSTRIDIUM DIFFICILE INFECTIONS, WITH A KEY PARTNER.TRIAL IS SCHEDULED TO BEGIN MID-2019.TEST DESIGN HAS BEEN IMPROVED FOR A BETTER ASSESSMENT OF DNV3837 EFFECTIVENESS IN TREATING CLOSTRIDIUM DIFFICILE INFECTIONS,.DEINOVE HAS CHOSEN MEDPACE AS ITS CLINICAL RESEARCH ORGANIZATION (CRO)(1) TO PREPARE AND OVERSEE TRIAL.THIS WILL BE A MULTICENTER TRIAL, TAKING PLACE MOSTLY IN UNITED STATES.  Full Article

Deinove To Market 2nd Proprietary Carotenoid-Based Cosmetic Active Ingredient In 2019
Thursday, 22 Nov 2018 

Nov 22 (Reuters) - DEINOVE SA ::DEINOVE WILL MARKET A 2ND PROPRIETARY CAROTENOID-BASED COSMETIC ACTIVE INGREDIENT IN 2019.THIS ACTIVE INGREDIENT, WHICH TARGETS A DERMOCOSMETIC INDICATION THAT IS ON RISE, WILL BE LAUNCHED IN 2019.FIRST EFFICACY TESTS CARRIED OUT IN ITS LABORATORIES HAVE BEEN PROMISING..  Full Article

Deinove Renews Its Equity Line
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - DEINOVE SA ::DEINOVE CONFIRMS ITS FINANCING OPTIONS BY RENEWING ITS EQUITY LINE.EQUITY LINE FUNDING SET UP IN DECEMBER 2014 EXPIRED.NEW EQUITY LINE, ONCE AGAIN STRUCTURED BY KEPLER CHEUVREUX, ADDS UP TO A MAXIMUM AMOUNT OF EUR 12 MILLION OVER 36 MONTHS..THIS NEW EQUITY LINE CAN BE SUSPENDED OR TERMINATED AT ANY TIME.REMAINING EUR 8 MILLION REMAIN SUBJECTED TO RESOLUTIONS THAT WILL BE PUT TO VOTE OF 2019 GENERAL MEETING..THIS RESERVE FUNDING CAPABILITY WILL REINFORCE DEINOVE'S CASH POSITION(2) AND ALLOW COMPANY TO FINANCE ITS OPERATIONS OVER NEXT TWELVE MONTHS.2,100,000 NEW SHARES ALLOWED TO BE SUBSCRIBED WITHIN SCOPE OF RESOLUTIONS PASSED BY 2018 GENERAL MEETING ADD UP TO APPROXIMATELY EUR 4 MILLION, BASED ON CURRENT STOCK PRICE.THIS NEW PROGRAM GIVES DEINOVE ADDITIONAL FINANCIAL FLEXIBILITY PARTICULARLY IN LIGHT OF UPCOMING START OF PHASE IIA CLINICAL TRIAL OF ITS ANTIBIOTIC CANDIDATE, DNV3837.  Full Article

Deinove To Collaborate With Calibr To Explore Anti-Infectious Potentials Of Its Bacterial Collection
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - DEINOVE SA ::DEINOVE TO COLLABORATE WITH CALIBR TO EXPLORE BROADLY THE ANTI-INFECTIOUS POTENTIALS OF ITS BACTERIAL COLLECTION.  Full Article

Deinove, Solvay Sign Partnership For Marketing Of Phytoene In North America And Asia
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - DEINOVE SA ::STRATEGIC PARTNERSHIP BETWEEN DEINOVE AND SOLVAY FOR THE MARKETING OF PHYTOENE IN NORTH AMERICA AND ASIA.SOLVAY NOVECARE WILL MARKET PHYTOENE AS A COSMETIC ACTIVE INGREDIENT IN NORTH AMERICA AND ASIA UNDER NAME REGEN-OPHYT.THE COLLABORATION COULD BE EXTENDED TO OTHER DEVELOPMENTS AT A LATER STAGE.THIS AGREEMENT COMPLETES PHYTOENE DISTRIBUTION STRATEGY FOR MAIN GEOGRAPHIES.  Full Article

Deinove Cash Position Of EUR 9.9 Million At June 30
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - DEINOVE SA ::DEINOVE: 2018 HALF-YEAR CONSOLIDATED RESULTS: STRENGTHENED FINANCIAL SITUATION SUBSTANTIAL PROGRESS IN BOTH AREAS OF BUSINESS.CASH POSITION: +EUR 9.9M AT JUNE 30, 2018 COMPARED TO +EUR 4.9M AT DECEMBER 31, 2017.HALF-YEAR NET LOSS OF GROUP: -EUR 3.7M VERSUS. -EUR 3.3M IN FIRST HALF OF 2017.H1 OPERATING LOSS EUR 4.4 MILLION VERSUS LOSS EUR 4.8 MILLION YEAR AGO.H1 TOTAL OPERATING REVENUES EUR 0.7 MILLION VERSUS EUR 0.1 MILLION YEAR AGO.  Full Article

Deinove In Partnership With Univar For Distribution Of Phyt-N-Resist In EMEA Zone
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - DEINOVE SA ::STRATEGIC PARTNERSHIP BETWEEN DEINOVE AND UNIVAR FOR THE DISTRIBUTION OF PHYT-N-RESIST® IN THE EMEA ZONE.  Full Article

Deinove And Oleos Expand Collaboration
Wednesday, 30 May 2018 

May 30 (Reuters) - DEINOVE SA ::DEINOVE AND OLEOS EXPAND THEIR COLLABORATION WITH THE SUPPORT OF THE OCCITANIE REGION.A SECOND COSMETIC ACTIVE INGREDIENT WILL BE DEVELOPED AS PART OF COLLABORATION.OCCITANIE REGION WILL FINANCE UP TO 35% OF THIS NEW PROJECT.  Full Article